Analyst Price Targets — TBPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:36 am | — | H.C. Wainwright | $17.00 | $17.00 | TheFly | Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright |
| March 4, 2026 7:11 am | Mayank Mamtani | B.Riley Financial | $14.00 | $13.96 | StreetInsider | B.Riley Downgrades Theravance Biopharma (TBPH) to Neutral |
| December 3, 2025 11:16 am | — | Oppenheimer | $27.00 | $18.43 | TheFly | Theravance Biopharma initiated with an Outperform at Oppenheimer |
| November 26, 2025 12:14 pm | — | BTIG | $40.00 | $18.94 | TheFly | Theravance Biopharma price target raised to $40 from $25 at BTIG |
| November 13, 2024 2:39 pm | David Risinger | Leerink Partners | $10.00 | $7.66 | StreetInsider | Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH) |
| August 6, 2024 6:08 am | Douglas Tsao | H.C. Wainwright | $15.00 | $9.59 | TheFly | Theravance Biopharma price target lowered to $15 from $20 at H.C. Wainwright |
| April 12, 2024 6:36 am | Julian Harrison | BTIG | $21.00 | $8.93 | StreetInsider | BTIG Starts Theravance Biopharma (TBPH) at Buy |
| November 17, 2022 6:03 am | — | Leerink Partners | $14.00 | $11.22 | Benzinga | SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14 |
Latest News for TBPH
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK PR Newswire
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue…
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 29, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH) PR Newswir
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TBPH.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.